Johnson & Johnson (JNJ) CEO Joaquin Duato has sold a major block of company stock just days after the healthcare giant reported mixed fourth-quarter results. According to the SEC filing, Duato sold about $22 million worth of JNJ shares on January 26. The sale involved about 120,000 shares executed at prices ranging roughly between $180 and $185. While insider transactions of this size often draw attention, the company’s stable performance suggests the move does not signal a shifting sentiment.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Despite the sale, Duato holds a substantial stake in the company, signaling his ongoing long-term alignment with shareholders. He still directly owns 275,967 shares and indirectly controls 110,486 shares.
Insider Sentiment for JNJ Stock Is Positive
TipRanks’ Insider Trading Activity Tool shows that insider confidence in the stock is currently Positive.
Investors may benefit from keeping an eye on transactions made by key insiders, as these trades typically reflect their trust in the company’s future. Interestingly, TipRanks offers daily insider transactions as well as a list of top corporate insiders. It also provides a list of hot stocks that boast either a Very Positive or Positive insider confidence signal.
Insider Sale Follows Q4 Earnings
Interestingly, the insider sale came within a week of J&J’s Q4 earnings report, which showed steady growth in its pharmaceutical division and improving momentum in medical technology. Also, the company provided a stronger-than-expected full-year outlook, highlighting strong demand for key drugs and continued progress in its MedTech pipeline.
As J&J works through product development, MedTech expansion, and ongoing legal pressures, the stock’s performance in the coming weeks will be closely watched by investors.
Is JNJ a Good Stock to Buy Now?
Turning to Wall Street, analysts have a Moderate Buy consensus rating on JNJ stock based on nine Buys and four Holds assigned in the past three months. Further, the average Johnson & Johnson stock price target of $241.25 per share implies 5.94% upside potential.
